完整後設資料紀錄
DC 欄位語言
dc.contributor.authorWu, Shou-Chengen_US
dc.contributor.authorChen, Jenen_US
dc.contributor.authorWang, Hsiang-Chingen_US
dc.contributor.authorChou, Min-Yuanen_US
dc.contributor.authorChang, Teng-Yuanen_US
dc.contributor.authorYuan, Shyng-Shiouen_US
dc.contributor.authorChen, Chiao-Yunen_US
dc.contributor.authorHou, Ming-Fengen_US
dc.contributor.authorHsu, John Tsu-Anen_US
dc.contributor.authorWang, Yun-Mingen_US
dc.date.accessioned2019-04-03T06:42:07Z-
dc.date.available2019-04-03T06:42:07Z-
dc.date.issued2016-01-01en_US
dc.identifier.issn1838-7640en_US
dc.identifier.urihttp://dx.doi.org/10.7150/thno.13069en_US
dc.identifier.urihttp://hdl.handle.net/11536/133583-
dc.description.abstractThe overexpression of HER2/neu and EGFR receptors plays important roles in tumorigenesis and tumor progression. Targeting these two receptors simultaneously can have a more widespread application in early diagnosis of cancers. In this study, a new multifunctional nanoparticles (MnMEIO-CyTE777-(Bis)-mPEG NPs) comprising a manganese-doped iron oxide nanoparticle core (MnMEIO), a silane-amino functionalized poly(ethylene glycol) copolymer shell, a near infrared fluorescence dye (CyTE777), and a covalently conjugated anti-HER2/neu and anti-EGFR receptors bispecific antibody (Bis) were successfully developed. In vitro T-2-weighted MR imaging studies in SKBR-3 and A431 tumor cells incubated with MnMEIO-CyTE777-(Bis)-mPEG NPs showed -94.8 +/- 3.8 and -84.1 +/- 2.8% negative contrast enhancement, respectively. Pharmacokinetics study showed that MnMEIO-CyTE777-(Bis)-mPEG NPs were eliminated from serum with the half-life of 21.3 mins. In vivo MR imaging showed that MnMEIO-CyTE777-(Bis)-mPEG NPs could specifically and effectively target to HER2/neu-and EGFR-expressing tumors in mice; the relative contrast enhancements were 11.8 (at 2 hrs post-injection) and 61.5 (at 24 hrs post-injection) fold higher in SKBR-3 tumors as compared to Colo-205 tumors. T2-weighted MR and optical imaging studies revealed that the new contrast agent (MnMEIO-CyTE777-(Bis)-mPEG NPs) could specifically and effectively target to HER2/neu-and/or EGFR-expressing tumors. Our results demonstrate that MnMEIO-CyTE777-(Bis)-mPEG NPs are able to recognize the tumors expressing both HER2/neu and/or EGFR, and may provide a novel molecular imaging tool for early diagnosis of cancers expressing HER2/neu and/or EGFR.en_US
dc.language.isoen_USen_US
dc.subjectbispecific antibodyen_US
dc.subjectMnMEIOen_US
dc.subjectmagnetic resonance imagingen_US
dc.subjectHER2/neuen_US
dc.subjectEGFRen_US
dc.titleBispecific Antibody Conjugated Manganese-Based Magnetic Engineered Iron Oxide for Imaging of HER2/neu- and EGFR-Expressing Tumorsen_US
dc.typeArticleen_US
dc.identifier.doi10.7150/thno.13069en_US
dc.identifier.journalTHERANOSTICSen_US
dc.citation.volume6en_US
dc.citation.issue1en_US
dc.citation.spage118en_US
dc.citation.epage130en_US
dc.contributor.department生物資訊及系統生物研究所zh_TW
dc.contributor.departmentInstitude of Bioinformatics and Systems Biologyen_US
dc.identifier.wosnumberWOS:000371806600003en_US
dc.citation.woscount13en_US
顯示於類別:期刊論文


文件中的檔案:

  1. 5fa30bed61d796e73588f4f2df8d2ab3.pdf

若為 zip 檔案,請下載檔案解壓縮後,用瀏覽器開啟資料夾中的 index.html 瀏覽全文。